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Objective
The aim of this study was to describe the current practice and to reach consensus of management in patients
with systemic juvenile idiopathic arthritis (sJIA) in the
Turkey.
Methods
Recommendations were established via consensus by a
panel of experts in pediatric rheumatology, based on
analysis of available scientific evidence obtained from
the clinical experience of panelists. The Delphi method
solicits the opinion of an expert panel through a carefully designed questionnaire which in this case included
questions on: epidemiology, diagnosis, treatment of
symptoms, drug choice, adverse events, follow-up visits,
hospital and emergency service admissions. The
responses were analyzed and discussed in a face to face
meeting followed by consensus building steps.
Results
Profiles of sJIA in Turkey were evaluated based on clinical experience of panelist. The percentage of patients
diagnosed with JIA was found 0,004% in the general
population in Turkey. Estimated number of JIA patients
was reported 342 per year. Twenty of them were diagnosed sJIA. Estimated sJIA patients were 55 per year.
The median age of diagnosis was 5.5 years. Consensus
was achieved on diagnosis of the patients which established by detail investigation inpatients clinics. Both
infectious and malignancy must be excluded in the
patients before diagnosis.
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The all sJIA patients was distributed according to subtypes; monocyclic 23%, polycyclic 30% and persistent/
polyarticular 47%. The mortality rate of sJIA patients
was found 1%. The most used drugs were reported as
glucocorticoid (100%), methotrexate (58%) and cyclosporine (10%), respectively. Etoposide and IVIG were
used only selected patients. In the treatment of disease
was determined to be the most preferred drug anakinra
after failure DMARDs therapies. Also, we determine
that canakinumab and tosilizumab were equally preferred (15-20%). The efficacy of the three drugs was
expressed as the same (80-90%). The selection criteria of
biological agents used in the treatment were reported:
joint involvement was evident, the presence of MAS,
characteristics of the patient, effective availability and
easy accessibility. The total duration of the treatment
was reported two years. The remission rates have been
reported to according to the course of the disease;
monophasic disease recovered as 100% while polycyclic
and poliarticular forms’ remission rate were reported
80% and 60%. The morbidity of polyarticular JIA has
been reported as high such as joint deformities, growth
retardation, delayed puberty, and osteoporosis.

Conclusions
This consensus, produced through a modified Delphi
process, reflects our current recommendations for the
diagnosis and management of sJIA in Turkey. The consensus statements are intended to serve as a reference
point for teaching, clinical practice, and research in
Turkey.
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